Pod Insights Pharmacy Podcast Network Compounding Advocacy in Heels: 2026 State Legislation Edition | Essential: The Pharmacy Compounding Podcast About this episode This episode we look at some of the latest compounding news, and then we’ve got a deep dive into state-level legislation with the Leading Ladies of Pharmacy Compounding Advocacy. What bills are being introduced? What do they really mean when you read the detail? How will they affect state policies, and what could come next? And, of course, how are APC and compounding pharmacies fighting back against the bad bills that put patients at risk? If you’re a compounder, if you have patients who use compounded medications, or if you’re a patient yourself, you’ll want to hear this. Links from the podcast:The FDA statement on excluding GLP-1s from bulk compounding: https://fllw.me/491oGl3FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C (part 1), https://fllw.me/4nxd13G (part 2)Is It Legit? to find a state-licensed compounding pharmacy: https://a4pc.org/isitlegitJoin APC! https://a4pc.org/join
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
0:24 Speaker 01 Welcome to Essential News and Analysis from the Alliance for Pharmacy Compounding. We are the voice for, well, pharmacy compounding. I'm your host, Andrew Cantor. We're going to give you a bit of compounding news before we get to the main event. We talk a lot about federal laws and FDA regulations, but today, we're going to take a deep dive into state level legislation that's been introduced this year. Specifically, the bills that are aimed at, obviously, pharmacy compounding and where they might lead. But first, the news.
0:58 Speaker 01 All right, this is good stuff. Congressman Michael Ruley of Ohio has introduced the Protecting Equal Access to Thyroid Act. That's PTE or PETA. It would rein in the FDA's reclassification of desiccated thyroid extract as a biologic. We are totally behind that because, well, DTE isn't a biologic. The only thing that's biological is thyroglobulin, and that's clinically inactive. There's no logical reason for the FDA's reclassification, and it cuts off access to compounded thyroid meds for millions of patients who rely on it. It's unfortunate that it might take an act of Congress to prevent this, but there you go. We'll keep you updated as it moves along.
1:44 Speaker 01 Well, it looked like big news, and apparently, a bunch of news outlets thought it was, but a recent FDA announcement is actually a whole lot of nothing. The FDA said it's planning to exclude semaglutide, terzepatide, and liraglutide from the 503b bulks list because the agency says that outside of a shortage, there's really no need for outsourcing facilities to compound them. And this changes nothing.
2:11 Speaker 01 Current regs already prohibit 503Bs from compounding those GLP-1s unless there's a shortage. Now, if the agency said it was planning to add those drugs to the bulks list, well, that would be a story. But nope, all it said was, "No, we'll stick with the status quo and keep those drugs off the bulks list." Still, the "we're not changing anything" announcement confused at least some news agencies, and they acted like it was a big deal. But once again, the FDA just said it wasn't changing anything about when 503B outsourcing facilities can compound GLP-1s. So really, nothing to see here. Move along, citizen, move along.
2:53 Speaker 01 The good folks at FDA Law Blog have posted a second part to their primer on the peptide compounding landscape. This time, they talk about the, uh, the long and winding road to regulated peptide compounding. There's definitely movement, but it's a process that could take a year or more, even if the road is pothole-free. The next step is a meeting of the Pharmacy Compounding Advisory Committee, and even if that committee recommends allowing compounding with peptides, first, the FDA has to agree. And then there's still the whole rulemaking process to go through. Then, there are supply chain issues, advertising restrictions, and a lot more, i's to dot and t's to cross.
3:35 Speaker 01 There's a link to the blog post in the show notes, and it's well worth a read, if only to get a clearer picture of what's really happening with peptides and compounding. Side note, stakeholders have until July 9th to submit written comments to the docket, so keep that in mind if you want to weigh in. Oh, and there's always the possibility that HHS Secretary RFK Jr. will unilaterally move to place certain peptides on the 503A bulks list and bypass the entire process. All right, I know what you're thinking, yes, that would still require notice and comment rulemaking, but it could be the start of an era of enforcement discretion pending that rulemaking. Maybe. I guess we'll see. And yes, ABC members, we will for sure keep you in the loop.
4:22 Speaker 01 One of the issues that comes up in pharmacy compounding is that there are a lot of, let's call them questionable websites out there that claim to be selling compounded medications. Actually, we'll call them what they really are. They are bogus sites, fake, possibly dangerous, and they confuse people, and to be fair, even legislators, who lump them in with legitimate compounding pharmacies. But if you're a patient, how do you tell what's legit pharmacy and what's a fake pop-up store? And that is where APC comes in. We've got a free tool that will help you check to see if a pharmacy you're thinking of using is actually licensed. We call it, "Is It Legit?" Catchy, right? You choose a state, enter the pharmacy name, and as long as you spelled it right, you'll
5:06 Speaker 01 find out whether it's legit or not. Easy peasy. That site? It's a4pc.org/iseitlegit. That's one word. There's also a link in the show notes to make it easy. And with that, it's time for our deep dive. This year, a dozen odd states have introduced legislation that affects compounding pharmacies, and in some cases, those bills have the fingerprints of Big Pharma all over them. So to talk about what's going on in which states and how some of it might spread around the country, we've got with us today the leading ladies of pharmacy compounding advocacy:
5:47 Speaker 01 Tanil Davis, Katie Johnston, Lauren Paul, and Sarah Witt. Tanil is, of course, APC's chief advocacy officer. Katie Johnston is at Revelation Pharma, where she oversees regulation and legislation all across 50 states and at the federal level. Lauren Paul is a licensed pharmacist in multiple states, and she's currently the director of state government affairs for him's and hers. And Sarah Witt is the advocacy lead for Strive Compounding Pharmacy, where she manages its federal and state advocacy efforts. They've all been heavily involved in tracking and responding to the kind of state-level legislation that impacts compounding pharmacies, and, you know, doing their part to educate people and even organize Grassroots Engagement efforts.
6:34 Speaker 01 Now that you know our experts, it's time to talk about that state level legislation. What's happened, what's pending, and where it's all going. Tanil, take it away.
6:44 Speaker 02 Thanks, Andrew. I'm really pleased today to welcome Sarah and Katie and Lauren to our podcast. We are the Ladies of Advocacy, and I was going to start out by having each one of them give a little bit of background into how they got into advocacy work. Most of us here are pharmacists by trade, and advocacy doesn't really lend itself to our scientific background. So what was the path that led you into the advocacy role that you hold now at your job? And I'm going to start with Lauren.
7:13 Speaker 03 Hi, thanks, Tanil. Great to be here. I started as a community pharmacist in one of our larger retail pharmacies and sort of worked my way throughout the organization into different roles and was plucked into the advocacy role over a decade ago. Really enjoy the advocacy side, being able to shape the practice of pharmacy and moving pharmacy practice forward within the profession.
7:42 Speaker 02 Awesome. How about Sarah?
7:44 Speaker 04 Yeah, thank you, Tanil. So really got my advocacy first introduced to me during my APY rotation, my fourth year pharmacy school. I had a pharmacy advocacy and leadership rotation, and I was on rotation with a Utah state senator here who's also a pharmacist. He kind of handed me a bill the first day and told me to run with it, and that was the beginning. And once I joined STRIVE, I really had the opportunity to attend CCH back in 2024 and really realized the need for it within STRIVE. And so ever since then, I've kind of been running with it, learning on the fly, and loving every minute of it.
8:27 Speaker 02 For those of you who don't know, Sarah is referring to Compounders on Capitol Hill, which is APC's yearly fly into Washington DC where pharmacy professionals in the compounding space fly over all into Washington DC and visit with their members of Congress, educating them on issues of I'll move to our non-pharmacist, but no less amazing, Katie Johnston.
8:50 Speaker 05 It's Tenille. Hello, everyone. Yes, I am not a pharmacist, but I have a background that's actually focused in government affairs and policy. Coming out of high school and going into college, I always had a super strong interest in American government and policy, but also healthcare at the same time. Biology was always my favorite subject, but kind of always assumed I did not have the skills and ability to be a doctor or pharmacist or anything that's actually on the ground in the field. So I kind of thought, you know, policy and healthcare, I can marry the two together going down this route. So my undergraduate degree is in political science, and then I got my master's in public administration with a specialty in healthcare policy. And since then, my career's been, you know, pretty much all government affairs roles. I've done a position with a pharmaceutical company.
9:35 Speaker 05 I've worked with NIH for a little bit. So I've gotten some experience on the local, state, and federal level. I joined Revelation about two and a half years ago, and learning the compounding space has definitely been a challenge, but it's been amazing. It's a great, great industry to be in. And despite the challenges we're facing, it's been a wonderful opportunity. So I'm happy to be here.
9:55 Speaker 02 Well, I appreciate you being here so much. We're going to talk about state-level legislation today, because I know most of our advocacy work has either been in the federal space with FDA, USP, or it's been in the state space with the state boards of pharmacy. But there's not very often that we, as advocacy ladies in the compounding space, get involved with state-level legislation. So I'm going to start out this wave of legislation that's been introduced. It really started, the first bills were introduced in December, if I remember, in Florida, and we've had quite a few since then. So let's start out by talking about kind of the bills that were introduced in Florida and kind of how it started the ball rolling to have legislation come along in about a dozen other states.
10:40 Speaker 02 So I'll start with Katie. Katie, will you talk a little bit about the two bills that were introduced in Florida in December and kind of what those bills look like and how, you know, kind of set the stage for the rest of the country?
10:52 Speaker 05 Yeah, absolutely. I think, you know, going into the end of the year, we were all caught off guard by this sudden wave of legislation. Florida, I think we felt good about going into it because of existing relationships we had there, but then we started getting our hands on some of the language that was included in these bills, and that's where the concern really came to be. And I know at first, there was legislation that would touch any compounding, not even just GLP-1s specifically, and that was super alarming. And, you know, fortunately, as we went through the past couple of months, it definitely refined down to being more focused on GLP-1s. But, you know, again, I think the biggest thing going into the end of the year, though, was we were all just so unprepared for what was coming. I don't think we realized the scale of it.
11:37 Speaker 05 And on top of that, you know, I think APC, the industry as a whole, hasn't faced an effort, like, an issue like this before, where it was, you know, multiple states, at the same time, you're working with a limited timeframe. You have some states who are in session for only two months, and then some who go all year long, along with, you know, limited resources. We haven't had to organize something like this before. So it was kind of a mad dash to how we're going to go about this, the approach we're going to take. But I think, all things considered, we did pretty darn good. But, um, yeah, I think that was probably the most concerning part. It was just how caught off guard we were.
12:09 Speaker 02 Yeah, we were absolutely caught off guard, and especially in Florida, we had a bill introduced kind of simultaneously in the Florida House and in the Florida Senate. Like you said, one of those bills would have restricted all of compounding, and one of them was a little bit more limited in that it applied only to weight loss drugs without defining what weight loss drugs were. So we were, you know, trying to analyze this new legislation and figure out what it meant. Would it apply to metformin? Would it apply to low-dose naltrexone? I mean, there's so many things that could be, yeah, used, you know, off-label for weight loss. So we talked about the bills that were introduced in Florida and how that kind of threw us
12:49 Speaker 02 off, but let's talk now about how they set the stage and they shared DNA with the legislation that was going to end up being filed in about a dozen states around the country. Lauren, can you kind of share some common themes in the legislation that ended up getting filed?
13:05 Speaker 03 Yeah, sure. I think what we saw across the country was requirements that were very similar in all the bills. Some of them effectively would limit all the compounding for GLP-1s. We did see a few that started off as prohibition of all compounding, and then through very early committee meetings, they were moved more into a prohibition on GLP-1 compounding. Some of the requirements we saw were that compounding pharmacies needed to buy API directly from the drug makers themselves. This was language that you really had to understand because it wasn't an outright saying that you had to buy from the drug
13:50 Speaker 03 makers. It was the way that it was worded, and it took a couple readings, I think, to identify that. I think what we also saw is API testing requirements, and then also more testing of finished compounded preparations that's above and beyond what FDA and USP standards, and would effectively put the compounds out of reach for patients. We also saw limits on sourcing from FDA-registered suppliers or manufacturers. They required that the API be sourced from FDA-registered suppliers that had been inspected within
14:29 Speaker 03 the last two years, receiving either a no action indicated or voluntary action indicated, which is a requirement not placed on any other FDA-registered manufacturers and is not how the FDA inspection process works, as it's a risk-based inspection. I think finally also, we saw some certificate of analysis requirements, which were above and beyond what is already required by the FDA.
14:56 Speaker 02 Yeah, a lot of these bills had language that was surprisingly similar. So it definitely appeared that there was someone behind all of these bills. And I think that we know who that is. And we're not going to name names or anything, but there's some big drug makers that were pushing this legislation in order to protect their market share. And a lot of the talking points that they used and that they had the lawmakers use when introducing these bills was around patient safety, that these were a bill to protect patient safety, talking about counterfeit drugs and illicit medications, even though these bills really would target legitimate compounding pharmacies.
15:37 Speaker 02 Katie, can you talk a little bit about the way that these bills were framed versus what these bills actually would do if they were passed as introduced?
15:45 Speaker 05 Yes, absolutely. I think that was honestly probably the biggest problem we faced was the narrative that was being created around compounding. Compounding plays a very important and valuable role in the healthcare space, and a lot of the dialogue that was being used around it being dangerous and unsafe was super concerning, even outside of GLP-1s. And in addition to that, I know some of the bills, they include language on deceptive advertising. And I think it's okay to explain that a compounded drug is not FDA-approved, they're not supposed to be FDA-approved, but including language such as it's unsafe just as a detriment to compounding as a whole. And that ultimately will hurt patient access.
16:29 Speaker 05 If you create this narrative that it's so dangerous, that legislators are going to be encouraged to want to restrict access to it. So for us, we had a big hurdle to face in terms of education and awareness on compounding and why it does exist. And for many legislators, compounding is such a very complex and specific issue. So going in meeting with them, you not only had to address the hurdle of what is compounding, but also what is it in the context of these bills and what these bills are trying to do. So I think that was a big part of our efforts and the planning coordination that went around it.
17:05 Speaker 02 So like I said, these bills have been introduced in about a dozen states. Sarah, can you talk a little bit about what we've done as an industry to fight some of this legislation? How APC has, you know, helped lead the charge in the states to get, you know, pharmacists to come testify? Can you talk a little bit about what the strategy has been in protecting compounding pharmacies in the states from this legislation getting further along?
17:32 Speaker 04 Yeah, Tenille. So a lot of what we've had to do as an industry is really correct the record on what compounding is, what compounding isn't, and really just take the time to educate these lawmakers on what we do on a day-to-day basis, how we fit into the healthcare ecosystem, how we support the pharmaceutical supply chain. We have a very unique role, and a lot of people don't know what that is. So it was a lot harder because we had to dig ourselves out of a hole of misconceptions, but I think we got there eventually, and we know that fight isn't over. So that's our main strategy, is really letting them know what compounding is.
18:15 Speaker 04 Then another strategy is just conveying to them what the effects of the bill would actually be to patients. You can see all of the legislation and the good intentions and what we would love to do to regulate the bad actors that operate outside of current regulations, but it's going to bleed over into compounding pharmacies who are licensed and operate under federal and state regulations. So really just putting a face to it and saying, there are patients out here who rely on compounded medications because they can't take a commercially available option. And when they do notice that, it is going to impact a lot more patients than they think
18:58 Speaker 04 and a lot more businesses than they realize, and taking away access and provider discretion. I think that's where they truly realized that this bill had unintended consequences, and we really needed to work on the legislation.
19:13 Speaker 05 And if I could just add to that, Neil, I think overall with all the legislation, my biggest concern was the precedent it was going to set for, you know, obviously GLP-1s were a blockbuster drug, something we've never dealt with before. And so that's not to say there's going to be another drug like that 10 years from now, 20 years from now. And so we don't want to set this precedent of putting pharmaceutical manufacturing-like standards onto compounding pharmacies, because that is not why compounding pharmacies exist. Compounding pharmacies exist to meet individual patient need, and the requirements and processes that, you know, pharmaceutical manufacturers have to go to cannot be met by a small compounding pharmacy. That is not what they are built and created to do.
19:54 Speaker 05 And so I think any of this legislation passing would just, again, set, you know, a very bad example for future drugs that would be similar to the craze of GLP-1s and how we treat compounding pharmacies when it comes to that space. Not including the fact that, you know, we played a critical role in meeting the gaps when these drugs were on shortage. So again, all that is just something I think that needs to be taken in consideration as we move forward.
20:17 Speaker 04 Exactly, Katie. Like, if they can target one class of medications, what's to say that they can't target HRT in the future, which is one of the biggest classes of medications that we compound for our patients? It has a huge impact for our patients in the industry.
20:36 Speaker 03 And if I could add to this also, I think one thing APC has done a really nice job at is really unwinding the narrative and the conflation between illicit and counterfeit drugs with compounding. We know that that has been a message that has been out there by some groups, and really needing to unwind that and explain the difference between the two has been a key in the education that APC has done during this legislative session.
21:05 Speaker 02 One of the things that APC learned as these bills were introduced around the country, you know, we hadn't had a whole lot of experience dealing with state-level legislation in the past, is kind of what the steps are needed to take when you're talking about defeating state legislation or changing state legislation. So, we had to, you know, say a bill is introduced in a particular state, we would run reports of all the pharmacies and pharmacists that were in that state to gather a group of, you know, people that would be actively involved in helping with getting the legislation stopped. So, the kind of people that would go in, make these visits, you know, to their legislators, either in their offices or invite them to their pharmacies. We hired lobbyists around the country. In most states, we ended up hiring a lobbyist.
21:50 Speaker 02 This was the first time that we've really ever hired these state-level lobbyists to deal with state legislative issues. You know, we've had a federal lobbyist for years, but these are, this is new. So, I was dealing with hiring and developing contracts with lobbyists all around the country and directing their activities, saying this is what we need to do to get these bills stopped.
22:11 Speaker 02 So, the first state that really had anything that actually went through that ended up crossing the finish line, and actually the only state, and we're going to cross our fingers and say the only state this year, was Indiana. And Indiana is a little bit different than some of the other states in the legislation that ended up getting passed. And Katie, do you want to talk a little bit about Indiana and how it was different than the kind of the other state legislation, which shared a lot of the same DNA?
22:40 Speaker 05 Yes, so for Indiana, that was kind of our first trial run in terms of how to actually treat the bill, how to triage it, how to get amendments in, how to work with legislators, and how to testify. And at the end of the day, you know, pharmacists, pharmacy owners, those are who are ultimately going to be affected by these bills. And so, that's who we want in there testifying. Except for most pharmacists, that's not something they're doing on a regular basis. So, you not only have the issue of having to recruit people quickly, but also get them up to speed on what the billing which is, how it'll affect them, and you know, how to, you know, successfully testify before the members of your legislature. And so fortunately with Indiana, it went through multiple rounds of amendments where
23:23 Speaker 05 we ultimately got it to where it essentially aligns with federal law, which I think we can all agree totally makes sense and we are happy with the outcome there, especially with that being the only bill, as you said, fingers crossed, hopefully the only bill that has passed. So I think Indiana was definitely our practice round. I think there was room for improvement as we were all kind of learning as we want the best way to go about it. But ultimately, I think we came out with a win there.
23:48 Speaker 02 The Indiana bill, like Katie said, did essentially just require compounding pharmacies to adhere to federal law, section 503A of the Food, Drug and Cosmetic Act. But it also created a registration system for med spas, which is different than much of the other legislation that's been introduced that kind of shares the same DNA we're talking about. Sarah or Lauren, does one of you want to talk about that med spa legislation and, you know, kind of where we think that the industry might go there?
24:19 Speaker 03 What we saw in Indiana was a requirement for registration for med spas, which had not been in the statute prior. There is some enforcement that will happen by the Board of Pharmacy, but the registration will happen for the med spas. This was something we did see the first time the American Med Spa Association come into the conversation. So there are some other requirements within that language, but really one of the only bills that addressed
24:57 Speaker 03 the med spa aspect of the GLP-1 compounding, or I would say more of the lifestyle treatment therapies that we see.
25:11 Speaker 02 There was one other bill that was introduced that with quite a bit of fanfare. Actually, there was a press conference that was done that included a patient that had taken a compounded GLP-1 and unfortunately had to have a liver transplant. And, you know, this press conference was with the executive director of the Board of Pharmacy in Kentucky, the patient, and the legislator that introduced it. And, you know, this press conference made it seem like the bill that was coming in Kentucky was going to be very similar to the bills that had been introduced around the country. But it actually ended up being really different. Katie, can you speak to the Kentucky bill at all?
25:51 Speaker 05 Yeah, the Kentucky bill totally caught us by surprise. I think when we found out about it, we had learned that it was connected to a patient and also the fact that the Board of Pharmacy helped drive some of the language that was included. And I think the Kentucky bill was a step in the right direction. You know, we definitely had some concerns within certain areas, but the overall goal of the bill was aligned with what we agree would be best done to control some of these bad actors that are out there. And, you know, I think when you compare the Kentucky bill to the legislation that we saw in other states, it's addressing the wide range of bad actors and focusing on unlicensed facilities, which where we believe is most of the concern is at.
26:33 Speaker 05 Whereas the legislation in the other states was focused solely on compounding pharmacies, which, you know, if there's a compounding pharmacy who's acting bad out there, there's already existing regulation to acknowledge that and address that. So if the other legislation passed, it would do nothing to address those outside bad actors, whereas the Kentucky bill would focus more on those and give the Board of Pharmacy the ability to step in when there was a cause for concern.
26:55 Speaker 04 I think the Kentucky bill was a really interesting example of where we kind of want this legislation to lead in the process that we need to have bringing more stakeholders to the table. If we're all trying to combat these bad actors and unlicensed entities entering the pharmacy space, we all need to work together on that because we all have different perspectives and we all come from different backgrounds to be able to make this what it needs to be. So the Kentucky bill, I think, is going to be interesting to see.
27:28 Speaker 02 Okay, so we've talked about some of the outliers like Indiana and Kentucky. So let's talk about the rest of them because we can kind of take the rest of the bills as a whole because they are so similar. Whether they, you know, applied to all compounded medications, which was the case in Washington, which is one of the reasons that that one was really, you know, relatively easy to defeat versus got limited only to compounded GLP-1s for weight loss, like Colorado that was relatively difficult to get that one postponed indefinitely, which is the status it's at now. Let's talk about those ones kind of as a group. All of those have either been killed in committee, timed out on calendar, or postponed indefinitely.
28:13 Speaker 02 So all around the country, those bills didn't advance, which tells us a lot about them because the legislators in those states really came to understand that these bills were bad for patient access to compounded medications. And I think that the legislators took some time to understand federal and state law and what already is required versus not required. Lauren, do you think that the legislators before the education by the pharmacist actually understood how compounding works under federal and state law?
28:44 Speaker 03 Danielle, it's a great question, and I think doing some of the visits myself and having some conversations, it's clear that there was a lack of understanding of how the legal and regulatory framework works, that, you know, pharmacies are very highly regulated by the FDA, but also they are state-regulated by already the legislatures. So there are state statutes and pharmacy acts that have specific language that regulate the state-licensed pharmacies, but also the state boards of pharmacy that also highly regulate these pharmacies.
29:23 Speaker 03 So it was clear that it was an education gap that was not given to them prior. And many of the legislatures aren't pharmacists. They don't understand that. We're very lucky to have a few that are and that understand and are advocates and allies. But unfortunately, the education was not there, but we got there through the session with all of the meetings and the education that we were all able to provide.
29:50 Speaker 02 Yeah, I've had the pleasure of flying out to many of these states to pay legislators some visits and do a little Compound N 101 and talk about these bills and how they would prevent patient access. And, you know, we've had pharmacists within these states that have gone on these visits as well. Sarah and I are actually just in Sacramento. I feel like that was last week to do visits and I'm setting up another time to go back. But Sarah, can you talk about the visits that we've had with state legislators and what those look like?
30:21 Speaker 04 Yeah, so those meetings really look like sitting down and getting into what the consequences of that bill's going to be. The bill in California was really framed as protecting people online from being targeted with ads. So there was a lot of misconceptions about what the bill really was. So we spent a lot of time really getting down into the weeds with this bill and letting them know exactly what this is going to do. It's going to take away patient access. It's going to severely limit what patients can and can't do with their health in the state of California.
31:06 Speaker 04 And so we spent a lot of time, I think we had 11 meetings in that one day. So it was a marathon of a day, but we were really able to connect with these lawmakers and tell them the direct impact it would have on their constituents and the people of California. It's really important to protect these people's health. And we were out there, we had, I think it was a whole group of pharmacists. We were all pharmacists out there. So we were really able to speak to what the consequences of this bill would be.
31:37 Speaker 02 Okay, you started, but we have to talk about California. Why has California been so uniquely challenging, do you think, Katie?
31:46 Speaker 05 The California Board of Pharmacy recently upgraded their USP standards and actually did more than what was required in USP. And so that's kind of been a challenge adapting to those additional requirements. Now, on top of that, we are facing what is arguably the most challenging legislative language that we've seen of all the bills in every state. You know, California, it's such a hub of healthcare and technology and innovation, and they have a very involved legislature. And so it's just been a much different culture and effort compared to what we've done in some of the other states.
32:19 Speaker 02 Yeah, the bill in California was introduced in the Assembly and it was triple-referred. So it actually had hearings in three different committees. And our drug makers that are pushing these bills have learned along the way, of course. We all learn from trial and error. And they found a tactic in California that really has resonated with California lawmakers. And in the committee hearing for privacy and consumer protection, it was quite an effective display for the people that were proponents of this bill and the Assemblyman who introduced this bill. Sarah, can you talk about the consumer protection angle that they're calling out in California?
32:56 Speaker 04 So the consumer protection angle was really viewing this through a lens of targeted social media advertising, which, like Tenille said, was very effective. We don't want people to be targeted with ads, to make them feel ashamed of who they are or how they look or what their bodies look like. And so that's really what they framed it as, and that stuck. And it stuck hard. It was really hard to get away from. And I think that people still think that that's what the bill is intended to do, is to limit those targeted social media advertisements.
33:37 Speaker 02 Yeah, in California, it's been a little bit different because unlike in other states where we really just opposed the legislation, in California, we authored and offered a complete set of amendments to the Assemblyman who introduced the bill. The amendments, you know, had advertising restrictions built into them, such as disclosures that compounded drugs are not FDA-approved, a complete prohibition on advertising that aimed at people under the age of 18. But we also included an entire new section in the bill that didn't exist before, surrounding the essentially a copy provisions in California. As, you know, was recently mentioned, California updated its compounding regulations and right
34:20 Speaker 02 now has the kind of most tight guardrails around compounding what is deemed, you know, quote-unquote, essentially a copy of an FDA-approved medication. Where most states follow the federal guidance, which requires a significant difference between FDA-approved and a compounded product to be documented by the pharmacy. But in California, there has to be a clinically significant difference. So this new section that we added into the bill actually defined clinically significant difference in a way that isn't in the California Board of Pharmacy Regulations in an attempt to make it easier for pharmacies to understand what documentation is enough, what is not enough, to kind of curtail any sort of widespread compounding
35:05 Speaker 02 under the guise of personalization. We did offer a complete set of amendments to the bill's author. They have not been accepted yet. We did have a meeting with the author to talk about these amendments. So we are hopeful that something will get accepted. You know, we would like something to pass in California that defines what essentially a copy is and that limits advertising to populations that shouldn't be advertised to and includes appropriate disclosures that compounded medications are not FDA-approved. But because of the way the bill has been framed in California and the way that California Assembly is focusing on this consumer safety, patient safety portion of the bill,
35:49 Speaker 02 which the majority of the bill is not about, and we don't really have a problem with that part of the bill, it's going to go to the full Assembly this coming week. And if it passes through the full Assembly, it'll move over to the Senate, and we'll start the process in the Senate over again. So California continues to be a challenge, and we continue to need support in California. So if you have patients in California, we have a grassroots initiative where you can send them to compounding.com. It'll send a message to their state Assemblyman or legislator explaining about the bill and what the problems with the bill are. If you have the ability to come with us to California, to Sacramento, to meet with these senators next, that would be helpful.
36:34 Speaker 02 So any way to get involved in this advocacy effort, if you've got patients in California, is appreciated. But looking forward, we're going to, you know, it's yet to be seen what's going to end up happening in California, but we do have next year to look forward to as well. Katie, can you talk to what we expect to see next legislative session?
36:54 Speaker 05 Yes, absolutely. I think next legislative session, I would argue, could potentially be even more of a battle in states where we didn't see anything pass. So basically, all of them except for Indiana right now. I think we'll probably see, I think we'll see pharma cut back a little bit on the language that they're using. I think after, you know, the multiple states that they had failure in this year, they're going to probably pivot their approach in terms of what they include language-wise. But I know for sure, Virginia, we're guaranteed to see a bill next year. I'm hearing rumors of Connecticut. Kentucky, we know will be coming back since it did not make it through in this session. So definitely rumors in all the states that we had legislation this year, along with some new ones that we never
37:37 Speaker 05 dealt with. And in addition to that, I know we've kind of been hearing of Pennsylvania and North Carolina on the side for a while to be introduced, but have not seen anything there. So if we don't get any movement out of those two states, I would go ahead and assume that they're going to be back next year as well. So I will say, while we're anticipating all of that, we, as an industry, are working on a more proactive approach as we go into next year. Again, this year, it was very much panic mode. We were caught off guard. We did the best we could with the limited time and resources we had. So hopefully, given everything we've learned over the past four months, we're going to be going in much stronger next year and prepared to have some of these conversations. And in addition to that, in the states where we've already had legislation, we've already
38:22 Speaker 05 initiated some of those conversations. So hopefully, you know, we have some of those relationships going where we've covered some of the basic education aspect of it. It can focus more on strategy and amending the bills to get them into a position where both sides are happy.
38:36 Speaker 02 Yeah, Katie, APC is working on a proactive approach. So rather than playing defense like we got to do this year, we've got a group of, you know, APC members that we have got Together, they're coming up with potential model legislation, visits with state legislators, you know, talking with attorney generals, just making a plan for how to go forward to prevent this kind of legislation from ever getting introduced in the first place because there's enough education, you know, in, in these lawmakers' offices that they, they know that this legislation is not good for patient access. So, looking forward, we're gonna, we're gonna have a long road ahead of us, a work still to do, um, before the,
39:21 Speaker 02 before next year. And a lot of this work also takes money. Lobbyists take money. So, if you haven't given to the Compounding Defense Fund, please consider giving to this fight. This fight is coming back next year. If you have given, please consider giving again. The fight is not over just because we got through 2026 mostly unscathed, you know, crossing our fingers about California. I think that's about it for our state legislative fight on our podcast today. Unless there's anything that anyone wants to add, um, I think that that is about it. If you have questions or comments or want to reach out to help, please reach out to me, Tenille. I'm leading the advocacy effort for APC. My
40:03 Speaker 02 email is my name, Tenille, T E N I L L E, A four P C dot org, and we'll put that in the show notes. And I'll give it back to you, Andrew.
40:11 Speaker 01 All right. Thank you, Tenille. Thank you, ladies. That was exactly the kind of perspective we really need these days when it, when it comes to those bills and, and the thought process behind some of this legislation. People don't always realize what's happening in their state legislatures, especially when you've got, let's say, some organizations deliberately trying to muddy the waters. All right. That is all for this episode of Essential. But before we play that outro music, something I always point out, if you are a compounding pharmacist or technician, or if you prescribe compounded meds, APC is almost certainly helping you and helping your patients. I'm not going to go through
40:55 Speaker 01 everything APC does, but I will say that it is the biggest, and in a good way, the loudest trade association for the whole compounding profession. If you're not a member of APC, you really ought to be. We are working for you. We'd love to have you on board. Just head over to A four P C dot org. Check us out. All right, Brady, now you can play that outro music. Thank you for listening, everyone.
41:28 Speaker 01 Brady.
Previous Birth Rights, Medical Bills & Legal Advocacy with Andi Orwoll, Esq. | MaternalRx Next Asembia's Specialty Pharmacy Summit Rewind 2026 | 6/6 Page updated November 14, 2026 · transcript and summary are machine-generated